Incyte Corporation (INCY) Stock Investment Calculator & Historical Return Analysis
Incyte Corporation is an American multinational biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in the areas of hematology, oncology, inflammation, and autoimmunity. The company aims to address unmet medical needs through innovative science. Investors often view Incyte Corporation as a key player in the market, analyzing its long-term potential through various revenue models, brand recognition, and consistent presence in its industry.
This Incyte Corporation stock investment calculator allows you to explore how a hypothetical investment in INCY might have performed over time. By adjusting the investment amount and time period, you can visualize potential growth, compare outcomes across different market cycles, and better understand the impact of long-term investing.
What if you invested $1000 in INCY on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Understanding Incyte Corporation's Historical Performance
Incyte Corporation's stock performance has historically reflected both broader market trends and company-specific milestones. Like many growth-oriented stocks, INCY has experienced periods of growth driven by innovation and market demand.
When analyzing Incyte Corporation's historical returns, it's important to consider:
- Market cycles: Strong bull markets often amplify returns, while recessions can temporarily suppress performance.
- Business model evolution: Changes in revenue strategies and product lines can significantly impact stability.
- Long-term trends: Over extended periods, compounding can play a larger role than short-term price fluctuations. Try our calculator to explore returns over 5 years or larger investments over 10 years.
This calculator helps you see how these factors might have affected an investment depending on when you entered the market.
Historical Annual Returns
Over the past 33 years, Incyte Corporation has delivered an average annual return of 24.3%. The stock peaked in 2013 with a massive +197.8% gain, while investors faced a downturn in 2002 (-76.5%). Overall, the stock finished in the green 21 times out of 33 years.
Avg Return
+24.3%
Win Rate
64%
21W - 12L
Best
+197.8%
2013
Worst
-76.5%
2002
Performance Consistency
Incyte Corporation Annual Returns by Year
| Year | Annual Return | Start Price | End Price |
|---|---|---|---|
| 1993 | +20.00% | $1.88 | $2.25 |
| 1994 | +58.57% | $2.19 | $3.47 |
| 1995 | +83.49% | $3.41 | $6.25 |
| 1996 | +83.11% | $7.03 | $12.88 |
| 1997 | +76.47% | $12.75 | $22.50 |
| 1998 | -12.57% | $21.38 | $18.69 |
| 1999 | +62.16% | $18.50 | $30.00 |
| 2000 | -44.51% | $44.83 | $24.88 |
| 2001 | -13.84% | $22.56 | $19.44 |
| 2002 | -76.49% | $19.40 | $4.56 |
| 2003 | +39.59% | $4.90 | $6.84 |
| 2004 | +46.48% | $6.82 | $9.99 |
| 2005 | -44.61% | $9.64 | $5.34 |
| 2006 | +9.36% | $5.34 | $5.84 |
| 2007 | +66.94% | $6.02 | $10.05 |
| 2008 | -62.02% | $9.98 | $3.79 |
| 2009 | +136.62% | $3.85 | $9.11 |
| 2010 | +74.32% | $9.50 | $16.56 |
| 2011 | -9.14% | $16.52 | $15.01 |
| 2012 | +10.81% | $14.99 | $16.61 |
| 2013 | +197.82% | $17.00 | $50.63 |
| 2014 | +42.71% | $51.23 | $73.11 |
| 2015 | +47.03% | $73.76 | $108.45 |
| 2016 | -2.95% | $103.32 | $100.27 |
| 2017 | -7.44% | $102.32 | $94.71 |
| 2018 | -36.97% | $100.89 | $63.59 |
| 2019 | +37.38% | $63.56 | $87.32 |
| 2020 | +1.17% | $85.97 | $86.98 |
| 2021 | -15.10% | $86.45 | $73.40 |
| 2022 | +8.58% | $73.97 | $80.32 |
| 2023 | -21.07% | $79.55 | $62.79 |
| 2024 | +5.53% | $65.45 | $69.07 |
| 2025 | +42.05% | $69.53 | $98.77 |
Historical annual returns for Incyte Corporation. Data shows year-over-year percentage change in stock price.
Why Use a "What If" Stock Calculator?
Many investors wonder questions such as:
- What if I had invested 5 years ago?
- How does timing affect long-term returns?
- What role does compounding play in stock investments?
A what-if investment calculator answers these questions by turning historical data into practical insights. Rather than focusing on daily price movements, it encourages a long-term perspective, which is especially useful for retirement planning, portfolio comparisons, and financial education.
Key Innovations
- ✓Discovery and development of several proprietary therapeutic products, such as Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (ruxolitinib cream), Iclusig (ponatinib), Zynyz (retifanlimab-dlwr), and Niktimvo (axatilimab-csfr), addressing various medical conditions.
- ✓Ongoing commitment to innovative scientific research to bring new treatments to patients with unmet medical needs.
Business Segments
- Hematology & OncologyFocuses on the development and commercialization of treatments for blood cancers and other oncological conditions.
- Inflammation & AutoimmunityEngages in research and development of therapies for inflammatory and autoimmune diseases.
How to Interpret the Results
The results shown are based on historical performance and are meant for educational and informational purposes only. They do not account for future market conditions, taxes, transaction fees, or individual investment strategies. Past performance does not guarantee future results, but historical analysis can help investors understand risk, volatility, and growth potential.
For best use:
- Compare multiple time ranges to see how outcomes differ
- Use consistent assumptions across different stocks
- Combine this tool with fundamental research and diversification principles